AbbVie
pharmaceutical company
ABBV NYSE
ISIN US00287Y1091 SEC CIK 1551152 LEI FR5LCKFTG8054YNNRU85
Follow AbbVie
Weekly email: filings, results
Revenue, last quarter
$17.4B
+10.3% vs same quarter last year
Net income
$4.2B
+2167.7% vs same quarter last year
EPS, diluted
$2.37
+2270% vs same quarter last year
Operating cash flow
$7.6B
+8.3% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | $61.2B | $4.2B |
| FY24 | $56.3B | $4.3B |
| FY23 | $54.3B | $4.9B |
| FY22 | $58.1B | $11.8B |
| FY21 | $56.2B | $11.5B |
| FY20 | $45.8B | $4.6B |
| FY19 | $33.3B | $7.9B |
| FY18 | $32.8B | $5.7B |
| FY17 | $28.2B | $5.3B |
| FY16 | $25.6B | $6B |
| FY15 | $22.9B | $5.1B |
| FY14 | $20B | $1.8B |
| FY13 | $18.8B | $4.1B |
| FY12 | $18.4B | $5.3B |
| FY11 | $17.4B | $3.4B |
- Gross margin
- Operating margin
- Net margin
Show the numbers
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| FY25 | 70.2% | 24.6% | 6.9% |
| FY24 | 70% | 16.2% | 7.6% |
| FY23 | 62.4% | 23.5% | 9% |
| FY22 | 70% | 31.2% | 20.4% |
| FY21 | 69% | 31.9% | 20.5% |
| FY20 | 66.4% | 24.8% | 10.1% |
| FY19 | 77.6% | 39% | 23.7% |
| FY18 | 76.4% | 19.5% | 17.4% |
| FY17 | 75% | 33.8% | 18.8% |
| FY16 | 77.3% | 36.4% | 23.2% |
| FY15 | 80.3% | 33% | 22.5% |
| FY14 | 77.8% | 17.1% | 8.9% |
| FY13 | 75.6% | 30.1% | 22% |
| FY12 | 75.5% | 31.6% | 28.7% |
| FY11 | 73.4% | 20.8% | 19.7% |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | $17.8B |
| FY24 | $17.8B |
| FY23 | $22.1B |
| FY22 | $24.2B |
| FY21 | $22B |
| FY20 | $16.8B |
| FY19 | $12.8B |
| FY18 | $12.8B |
| FY17 | $9.4B |
| FY16 | $6.6B |
| FY15 | $7B |
| FY14 | $2.9B |
| FY13 | $5.8B |
| FY12 | $6B |
| FY11 | $5.9B |
- Dividends
- Buybacks
Show the numbers
| Year | Dividends | Buybacks |
|---|---|---|
| FY25 | $11.7B | $980M |
| FY24 | $11B | $1.7B |
| FY23 | $10.5B | $2B |
| FY22 | $10B | $1.5B |
| FY21 | $9.3B | $934M |
| FY20 | $7.7B | $978M |
| FY19 | $6.4B | $629M |
| FY18 | $5.6B | $12B |
| FY17 | $4.1B | $1.4B |
| FY16 | $3.7B | $6B |
| FY15 | $3.3B | $7.6B |
| FY14 | $2.7B | $665M |
| FY13 | $2.6B | $320M |
| FY12 | - | - |
| FY11 | - | - |
- AbbVie
- Healthcare median
Show the numbers
| Year | AbbVie | Healthcare median |
|---|---|---|
| FY25 | 6.9% | −30.6% |
| FY24 | 7.6% | −47% |
| FY23 | 9% | −58% |
| FY22 | 20.4% | −80.4% |
| FY21 | 20.5% | −71.9% |
| FY20 | 10.1% | −62.2% |
| FY19 | 23.7% | −46.3% |
| FY18 | 17.4% | −49.6% |
| FY17 | 18.8% | −45.9% |
| FY16 | 23.2% | −36% |
| FY15 | 22.5% | −38.4% |
| FY14 | 8.9% | −35.5% |
| FY13 | 22% | −37.1% |
| FY12 | 28.7% | −29.1% |
| FY11 | 19.7% | −27.9% |